Clinical Trial Award – HT942526SCIRPCTA
- Pre-applications due 3 August 2026
- Up to USD$4.8M (Single PI Option) or USD$4.96M (Early-Career Partnership Option) over 4 years
- Supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of SCI.
- Projects may range from small proof-of-concept trials to demonstrate feasibility or inform the design of more advanced trials, through large-scale trials to determine efficacy in relevant populations.
- Utilization of decentralized clinical trial strategies that leverage virtual elements/tools for participant enrolment, communication, and data collection is especially encouraged.
- Applications must name at least two community partners who will provide advice and consultation throughout the planning and implementation of the research project.
- Applications must address at least one priority area and an associated near-term goal.
- Apply here
- Document – Program Announcement – HT942526SCIRPCTA_GG
Clinical Translation Research Award – HT942526SCIRPCTRA
- Pre-applications due 3 August 2026
- Up to USD$2M (Single PI Option) or USD$2.16M (Early-Career Partnership Option) over 3 years
- Supports high-impact, new or emerging clinical research that requires additional preliminary studies, such as feasibility, pilot or optimization, to prepare for larger-scale clinical trials.
- Primary objectives of this mechanism include:
- Accelerating translation of current and emerging techniques or interventions into clinical use by addressing specific barrier(s) to clinical success for the purpose of de-risking or informing the design of definitive trials.
- Identifying the most effective diagnosis, treatment and rehabilitation options to support critical decision-making for patients, clinicians, care partners and policymakers
- Studies may be interventional or observational and may involve some retrospective data analysis. Purely retrospective or data-base related research not allowed
- Clinical research or clinical trials required
- Animal research not allowed
- Applications must name at least two community partners who will provide advice and consultation throughout planning and implementation.
- Applications must address at least one priority area and an associated near-term goal.
- Apply here
- Document – Program Announcement – HT942526SCIRPCTRA_GG
Translational Research Award – HT942526SCIRPTRA
- Pre-applications due 3 August 2026
- Up to USD$2M (Single PI Option) or USD$2.16M (Early-Career Partnership Option) over 3 years
- Supports translational research to accelerate the movement of promising ideas in SCI research toward clinical application.
- Preclinical animal studies and/or clinical research involving human subjects and human anatomical substances are allowed.
- May include a pilot clinical trial ONLY as a part of the proposed research where limited clinical testing of a novel intervention or device is necessary to inform the next step in the continuum of translational research.
- Applications must name at least one community partner who will provide advice and consultation throughout planning and implementation.
- Applications must address at least one priority area and an associated near-term goal.
- Apply here
- Document – Program Announcement – HT942526SCIRPTRA_GG
Investigator-Initiated Research Award – HT942526SCIRPIIRA
- Pre-proposals due 3 August 2026
- Up to USD$800,000 (Single PI Option) or USD$960,000 (Early-Career Partnership Option) over 3 years
- Supports studies with the potential to make an important contribution to SCI research, patient care and/or quality of life.
- Permitted research includes preclinical studies in animal models, research with human subjects or human anatomical substances, as well as ancillary studies associated with an existing clinical trial.
- Preliminary data required.
- Clinical trials not allowed.
- Applications must address at least one priority area and an associated near-term goal.
- Apply here
- Document – Program Announcement – HT942526SCIRPIIRA_GG
Priority Areas and Goals
Acute Injury Intervention
- Near-Term Goal: Develop and test interventions, e.g., surgical, device, pharmacologic, to preserve and/or protect spinal cord tissue within a clinically feasible timeframe for improved neurologic outcomes relevant to the civilian and/or battlefield/deployed environment
- Long-Term Goal: Adoption of acute SCI management/stabilization practices within the battlefield, pre-hospital or hospital environments that meaningfully improve outcomes
Secondary Health Effects
- Near-Term Goal: Develop and test interventions to address secondary health effects of SCI that impact injury survivors throughout their full lifespan
- Long-Term Goal: Adoption of interventions that address secondary health effects of SCI
Psychosocial issues
- Near-Term Goal: Develop and test interventions that address psychosocial issues and that are specifically tailored for people with SCI, their families and/or their care-partners.
- Long-Term Goal: Adoption of interventions that promote psychosocial well-being for people with SCI, their families and/or their care-partners.
Rehabilitation and Regeneration
- Near-Term Goal A: Develop and test rehabilitation strategies that meaningfully improve functional recovery after SCI
- Near-Term Goal B: Develop and test regenerative/neuroplastic interventions that meaningfully improve outcomes after SCI
- Long-Term Goal: Adoption of interventions/techniques that meaningfully improve outcomes after SCI
